Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease.

Autor:	Vila-Castelar C; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Chen Y; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Langella S; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Lopera F; Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.; UK Dementia Research Institute at UCL, London, UK.; Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China., Hansson O; Memory Clinic, Skåne University Hospital, Malmö, Sweden.; Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden., Dage JL; Indiana University School of Medicine, Indianapolis, Indiana, USA., Janelidzde S; Memory Clinic, Skåne University Hospital, Malmö, Sweden., Su Y; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Chen K; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Pluim McDowell C; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts, USA.; Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Martinez JE; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts, USA., Ramirez-Gomez L; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Garcia G; Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia., Aguillon D; Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia., Baena A; Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia., Giraldo-Chica M; Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia., Protas HD; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Ghisays V; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Rios-Romenets S; Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia., Tariot PN; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Reiman EM; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Quiroz YT; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2023 Sep; Vol. 19 (9), pp. 4127-4138. Date of Electronic Publication: 2023 Jun 06.
DOI:	10.1002/alz.13314
Abstrakt:	Introduction: Plasma tau phosphorylated at threonine 217 (P-tau217) and neurofilament light (NfL) have emerged as markers of Alzheimer's disease (AD) pathology. Few studies have examined the role of sex in plasma biomarkers in sporadic AD, yielding mixed findings, and none in autosomal dominant AD. Methods: We examined the effects of sex and age on plasma P-tau217 and NfL, and their association with cognitive performance in a cross-sectional study of 621 Presenilin-1 E280A mutation carriers (PSEN1) and non-carriers. Results: As plasma P-tau217 levels increase, cognitively unimpaired female carriers showed better cognitive performance than cognitively unimpaired male carriers. Yet, as disease progresses, female carriers had a greater plasma NfL increase than male carriers. There were no sex differences in the association between age and plasma biomarkers among non-carriers. Discussion: Our findings suggest that, among PSEN1 mutation carriers, females had a greater rate of neurodegeneration than males, yet it did not predict cognitive performance. Highlights: We examined sex differences in plasma P-tau217 and NfL in Presenilin-1 E280A (PSEN1) mutation carriers and non-carriers. Female carriers had a greater plasma NfL increase, but not P-tau217, than male carriers. As plasma P-tau217 levels increase, cognitively unimpaired female carriers showed better cognitive performance than cognitively unimpaired male carriers. The interaction effect of sex by plasma NfL levels did not predict cognition among carriers. (© 2023 the Alzheimer's Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu